0000000000144602

AUTHOR

Giorgia Teresa Maniscalco

showing 11 related works from this author

Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register.

2022

Background: Definitions for reliable identification of transition from relapsing-remitting multiple sclerosis (MS) to secondary progressive (SP)MS in clinical cohorts are not available. Objectives: To compare diagnostic performances of two different data-driven SPMS definitions. Methods: Data-driven SPMS definitions based on a version of Lorscheider’s algorithm (DDA) and on the EXPAND trial inclusion criteria were compared, using the neurologist’s definition (ND) as gold standard, in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), Akaike information criterion (AIC) and area under the curve (AUC). Results: A cohort of 10,240 MS patients wi…

Multiple SclerosisMultiple Sclerosis Chronic ProgressiveMultiple sclerosisMultiple Sclerosis Relapsing-RemittingNeurologybig dataArea Under Curvedata-driven algorithmdisease registrysecondary progressiveHumansSettore MED/26 - NeurologiaNeurology (clinical)prognosisMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study

2022

Portaccio et al. report that in early relapsing-onset multiple sclerosis, progression independent of relapse activity is an important contributor to disability accumulation. Insidious progression occurs even in the earliest disease phases, suggesting that inflammation and degeneration may represent a single disease continuum.Disability accrual in multiple sclerosis may occur as relapse-associated worsening or progression independent of relapse activity. The role of progression independent of relapse activity in early multiple sclerosis is yet to be established. The objective of this multicentre, observational, retrospective cohort study was to investigate the contribution of relapse-associa…

Multiple Sclerosisrelapse-associated worseningprogression independent of relapse activityrelapsing multiple sclerosisCohort StudiesMultiple Sclerosis Relapsing-Remittingrelapse associated worseningRecurrenceChronic DiseaseDisease ProgressionHumansSettore MED/26 - NeurologiaNeurology (clinical)Retrospective Studies
researchProduct

mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis

2021

Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system. A novel coronavirus, namely SARS-CoV-2, has been recently responsible for the highly infectious disease referred as COVID-19, rapidly spreading all over the world. Many vaccines have been developed to control COVID-19 pandemic, including the mRNA vaccines Pfizer/BioNTech (BNT162b2) and Moderna (mRNA1273).1 The vaccination of people with MS (pwMS) has been recommended by several national and international MS societies. However, effectiveness and safety of anti-COVID-19 mRNA vaccines in MS need to be confirmed. The aim of this study was to evaluate the short-term risk of clinical relapses in pwMS in …

Pediatricsmedicine.medical_specialtyeducation.field_of_studyExpanded Disability Status ScaleCoronavirus disease 2019 (COVID-19)business.industryMultiple sclerosisCOVID-19; multiple sclerosis; neuroimmunologyPopulationCOVID-19neuroimmunologymedicine.diseasemultiple sclerosisVaccinationPsychiatry and Mental healthInfectious disease (medical specialty)multiple sclerosiPandemicmedicineSurgeryObservational studymultiple sclerosis neuroimmunology COVID-19Neurology (clinical)businesseducation
researchProduct

Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study

2019

Abstract Background The prevalence of trigeminal neuralgia (TN) in Multiple Sclerosis (MS) patients is higher than in the general population and its management can be particularly challenging. Our aim is to describe the characteristics, treatment and prognostic factors of MS-related TN in a retrospective multicentre study. Methods Neurologists members of the RIREMS group (Rising Researchers in MS) enrolled MS patients with a TN diagnosis and filled out a spreadsheet comprising their clinical data. Results Population consisted of 298 patients. First-choice preventive treatments were carbamazepine and oxcarbazepine. A surgical procedure was performed in 81 (30%) patients, most commonly gamma …

Pediatricsmedicine.medical_treatmentmultiple sclerosismicrovascular decompression surgerytime factors0302 clinical medicineRadiofrequency thermocoagulationTrigeminal neuralgiaMultiple SclerosiOutcome Assessment Health Careitalymiddle agedpain030212 general & internal medicineOxcarbazepinehumanseducation.field_of_studytrigeminal neuralgiaadultDisability; Multiple Sclerosis; Pain; Trigeminal neuralgiaradiosurgeryGeneral MedicineAnalgesics Non-Narcotichealth carefollow-up studiesSettore MED/26 - NEUROLOGIAagedretrospective studiesfemaleNeurologydisability; multiple sclerosis; pain; trigeminal neuralgia; adult; aged; analgesics non-narcotic; female; follow-up studies; humans; italy; male; microvascular decompression surgery; middle aged; multiple sclerosis; radiosurgery; retrospective studies; severity of illness index; sex factors; time factors; trigeminal neuralgia; neurosurgical procedures; outcome assessment health careanalgesicsTrigeminal neuralgiamedicine.drugmedicine.medical_specialtyMultiple SclerosisPopulationPainMicrovascular decompression03 medical and health sciencesmalemedicineseverity of illness indexeducationoutcome assessmentDisabilitybusiness.industryMultiple sclerosisCarbamazepinemedicine.diseaseneurosurgical proceduresDiscontinuationsex factorsdisabilitynon-narcoticNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience

2020

Background: Rituximab, an anti-CD20 monoclonal antibody leading to B lymphocyte depletion, is increasingly used as an off-label treatment option for multiple sclerosis (MS). Objective: To investigate the effectiveness and safety of rituximab in relapsing–remitting (RR) and progressive MS. Methods: This is a multicenter, retrospective study on consecutive MS patients treated off-label with rituximab in 22 Italian and 1 Swiss MS centers. Relapse rate, time to first relapse, Expanded Disability Status Scale (EDSS) progression, incidence of adverse events, and radiological outcomes from 2009 to 2019 were analyzed. Results: A total of 355/451 enrolled subjects had at least one follow-up visit an…

Multiple Sclerosismedicine.drug_classLymphocyte depletionrelapsing–remittingMonoclonal antibodyPrimary progressive03 medical and health sciences0302 clinical medicineMultiple Sclerosis Relapsing-Remittingreal lifemedicineHumansImmunologic Factors030212 general & internal medicineSecondary progressiveRetrospective Studiesprimary progressivebusiness.industryMultiple sclerosisRituximab; multiple sclerosis; primary progressive; real life; relapsing–remitting; secondary progressiveTreatment optionsmedicine.diseaseNeurologyRelapsing remittingItalymultiple sclerosiImmunologysecondary progressiveRituximabSettore MED/26 - NeurologiaNeurology (clinical)businessRituximab030217 neurology & neurosurgerySwitzerlandmedicine.drug
researchProduct

Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals' perspective

2022

Abstract Objective Multiple sclerosis (MS) is a chronic disease with different clinical courses and a tendency to worsening. The relapsing–remitting MS presents acute onset and relapses of neurological symptoms, followed by their remission. This form can convert to secondary progressive MS (SPMS) with irreversible neurological worsening and disability. The identification of signs, symptoms, markers of progression, and strategies to manage MS patients is mandatory to allow early identification of those at higher risk of conversion to SPMS, for prompt intervention to cope with the progression of the disease. Methods A panel of Italian experts from Southern Italy have reviewed the current know…

Secondary progressive multiple sclerosis (SPMS)DermatologyGeneral MedicineBiomarkerMultiple Sclerosis Chronic ProgressiveMultiple sclerosisPsychiatry and Mental healthMultiple Sclerosis Relapsing-RemittingItalyExpert opinionDiagnosisQuality of LifeDisease ProgressionHumansMultiple sclerosiSettore MED/26 - NeurologiaNeurology (clinical)Neoplasm Recurrence LocalAtrophyDelivery of Health CareBiomarkersDiagnosi
researchProduct

Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study

2022

Background and ObjectivesSeveral studies have assessed risk factors associated with the severity of COVID-19 outcomes in people with multiple sclerosis (PwMS). The potential role of disease-modifying therapies (DMTs) and demographic and clinical factors on the risk of acquiring SARS-CoV-2 infection has not been evaluated so far. The objective of this study was to assess risk factors of contracting SARS-CoV-2 infection in PwMS by using data collected in the Italian MS Register (IMSR).MethodsA case-control (1:2) study was set up. Cases included PwMS with a confirmed diagnosis of COVID-19, and controls included PwMS without a confirmed diagnosis of COVID-19. Both groups were propensity score–m…

AdultMaleMultiple SclerosisTime Factors41Dimethyl FumarateSex FactorRelapsing-RemittingSeverity of Illness IndexArticleImmunosuppressive AgentSex FactorsMultiple Sclerosis Relapsing-RemittingRisk FactorsMultiple SclerosiOdds RatioHumansAge Factor36053g COVID-19Fingolimod HydrochlorideSARS-CoV-2NatalizumabRisk FactorAge FactorsCOVID-19Glatiramer AcetateInterferon-betaMiddle AgedMultiple Sclerosis Chronic Progressive323Chronic ProgressiveNeurologyItalyCase-Control StudiesAdult; Age Factors; COVID-19; Case-Control Studies; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis Chronic Progressive; Multiple Sclerosis Relapsing-Remitting; Natalizumab; Odds Ratio; Risk Factors; SARS-CoV-2; Severity of Illness Index; Sex Factors; Time FactorsFemaleNeurology (clinical)Case-Control StudieImmunosuppressive AgentsHuman
researchProduct

A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.

2018

In this independent, multicenter, retrospective study, we investigated the short-term persistence to treatment with first-line self-injectable or oral disease-modifying treatments (DMTs) in patients with relapsing–remitting multiple sclerosis. Data of patients regularly attending 21 Italian MS Centres who started a self-injectable or an oral DMT in 2015 were collected to: (1) estimate the proportion of patients discontinuing the treatment; (3) explore reasons for discontinuation; (3) identify baseline predictors of treatment discontinuation over a follow-up period of 12 months. We analyzed data of 1832 consecutive patients (1289 women, 543 men); 374 (20.4%) of them discontinued the prescrib…

MaleInjectionTime FactorsPatient Dropoutdisease-modifying therapies; multiple sclerosis; outcome measurement; persistence to treatment; quality of lifeAdministration OralSelf AdministrationSex FactorKaplan-Meier EstimateRelapsing-Remittingmultiple sclerosisImmunologic Factor0302 clinical medicineQuality of lifeRetrospective StudieRisk FactorsMedicine030212 general & internal medicineDisease-modifying therapiedisease-modifying therapiesDisease-modifying therapies Multiple sclerosis Outcome measurement Persistence to treatment Quality of life Administration Oral Adult; Female Follow-Up Studies Humans Immunologic Factors Injections Kaplan-Meier EstimateMale Multiple Sclerosis Relapsing-Remitting Patient Dropouts Prognosis Proportional Hazards Models Retrospective Studies Risk Factors Self Administration Sex Factors Time FactorsHazard ratioPrognosisNeurologyTolerabilityAdministrationSettore MED/26 - NeurologiaFemaleoutcome measurementHumanOralAdultmedicine.medical_specialtyPatient DropoutsTime FactorPrognosiFollow-Up StudieInjections03 medical and health sciencesRoute of administrationMultiple Sclerosis Relapsing-RemittingSex FactorsInternal medicineHumansImmunologic FactorsMultiple sclerosiAdverse effectProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelRisk FactorRetrospective cohort studyDiscontinuationDisease-modifying therapies; Multiple sclerosis; Outcome measurement; Persistence to treatment; Quality of life; Administration Oral; Adult; Female; Follow-Up Studies; Humans; Immunologic Factors; Injections; Kaplan-Meier Estimate; Male; Multiple Sclerosis Relapsing-Remitting; Patient Dropouts; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Self Administration; Sex Factors; Time Factorsquality of lifeProportional Hazards Modelpersistence to treatmentNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up StudiesJournal of neurology
researchProduct

Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register

2021

AbstractThe current study aims to compare injectable and oral first-line disease-modifying therapies (DMTs) for time to first relapse, time to confirmed disability progression (CDP), and time to discontinuation using a cohort of relapsing remitting multiple sclerosis (RRMS) patients, with data extracted from the Italian MS Register. This multicenter, observational, retrospectively acquired, and propensity-adjusted cohort study utilized RRMS-naïve patients from the Italian MS Register who started either injectable or oral first-line DMTs between January 1, 2010, and December 31, 2017, to evaluate the impact on disability outcomes in patients. Enrolled patients were divided into two groups, n…

Maleoral DMTsoral DMTAdministration OralDiseaseRelapsing-RemittingCohort Studies0302 clinical medicineImmunologicinjectable DMTPharmacology (medical)030212 general & internal medicineRegistriesSubcutaneousMiddle AgedItalyEDSS score; injectable DMTs; Multiple sclerosis; oral DMTs; real-world setting; Adjuvants Immunologic; Administration Oral; Adult; Cohort Studies; Female; Follow-Up Studies; Glatiramer Acetate; Humans; Immunologic Factors; Injections Subcutaneous; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis Relapsing-Remitting; Retrospective Studies; RegistriesAdministrationCohortSettore MED/26 - NeurologiaOriginal ArticleFemaleNeurosurgeryCohort studyOralAdultmedicine.medical_specialtyEDSS scoreInjections SubcutaneousLower riskInjectionsMultiple sclerosis03 medical and health sciencesMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicInternal medicinereal-world settingmedicineHumansImmunologic FactorsMultiple sclerosiAdjuvantsinjectable DMTsRetrospective StudiesPharmacologybusiness.industryMultiple sclerosisGlatiramer AcetateInterferon-betamedicine.diseaseDiscontinuationObservational studyNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies

2021

Background and aims: No consensus exists on how aggressively to treat relapsing–remitting multiple sclerosis (RRMS) nor on the timing of the treatment. The objective of this study was to evaluate disability trajectories in RRMS patients treated with an early intensive treatment (EIT) or with a moderate-efficacy treatment followed by escalation to higher-efficacy disease modifying therapy (ESC). Methods: RRMS patients with ⩾5-year follow-up and ⩾3 visits after disease modifying therapy (DMT) start were selected from the Italian MS Registry. EIT group included patients who received as first DMT fingolimod, natalizumab, mitoxantrone, alemtuzumab, ocrelizumab, cladribine. ESC group patients rec…

Pediatricsmedicine.medical_specialtybig data; disability trajectories; disease registry; multiple sclerosis.multiple sclerosis03 medical and health sciences0302 clinical medicineDisease registrybig dataMedicine030212 general & internal medicineRC346-429Original Researchbig data; disability trajectories; disease registry; multiple sclerosisPharmacologybusiness.industryMultiple sclerosisLong term disabilitymedicine.diseaseNeurologydisease registryTreatment strategySettore MED/26 - Neurologiadisability trajectoriesNeurology. Diseases of the nervous systemNeurology (clinical)business030217 neurology & neurosurgeryTherapeutic Advances in Neurological Disorders
researchProduct

Comparing Natural History of Early and Late Onset Pediatric Multiple Sclerosis

2022

Objective: This study was undertaken to describe and compare disease course and prognosis of early (ie, disease onset before age 11 years) and late (ie, disease onset after age 11 years) onset pediatric multiple sclerosis. Methods: Prospectively collected clinical information from Italian Multiple Sclerosis Register of 1993 pediatric multiple sclerosis patients, of whom 172 had early onset, was analyzed. Cox models adjusted for sex, baseline Expanded Disability Status Scale score, and disease-modifying treatments and stratified for diagnostic criteria adopted (Poser vs McDonald) were used to assess the risk of reaching irreversible Expanded Disability Status Scale scores of 3, 4, and 6, and…

MaleNatural History of Multiple SclerosisMultiple SclerosisNeurologyRecurrencePediatric Multiple SclerosisDisease ProgressionHumansDisabled PersonsSettore MED/26 - NeurologiaNeurology (clinical)ChildPrognosis
researchProduct